[1]Teng YH, Aquino RS, Park PW. Molecular functions of Syndecan-1 in disease[J]. Matrix Biol, 2012, 31:3-16.
[2]Akl MR, Nagpal P, Ayoub NM, et al. Molecular and clinical profiles of Syndecan-1 in solid and hematological cancer for prognosis and precision medicine[J].Oncotarget, 2015, 6(30):28693-28715.
[3]Pasqualon T, Pruessmeyer J, Weidenfeld S, et al. A transmembrane C-terminal fragment of Syndecan-1 is generated by the metalloproteinase ADAM17 and promotes lung epithelial tumor cell migration and lung metastasis formation[J].Cell Mol Life Sci, 2015,72(19):3783-3801.
[4]Dobre M, Dinu DE, Panaitescu E, et al. K-Ras gene mutations-prognostic factor in colorectal cancer[J] ? Rom J Morphol Embryo, 2015, 56(2 Suppl):671-678.
[5]Alves S, Castro L, Fernandes MS.Colorectal cancer-related mutant K-Ras alleles function as positive regulators of autophagy[J].Oncotarget, 2015, 6(31):30787-30802.
[6]Barresi V, Bonetti LR, Bettelli S. K-Ras, N-Ras, B-RAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases[J].Pathology, 2015, 47(6):551-556.
[7]Spindler KL, Pallisgaard N, Appelt AL,et al. Clinical utility of K-Ras status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy[J].Eur J Cancer, 2015, 51(17):2678-2685.
[8]Marino A, Caliolo C, Sponziello F, et al. Panitumumab after progression on cetuximab in K-RAS wild-type metastaticcolorectal cancer patients: a single institution experience[J].Tumori, 2015,101 (5):524-528.
[9]Kusumoto T, Kodama J, Seki N, et al. Clinical significance of Syndecan-1 and versican expression in human epithelial ovariancancer[J]. Oncol Rep, 2010, 23(9): 917-925.
[10]周霞辉, 吴成就,肖乐东,等.焦磷酸测序技术检测K-RAS基因突变方法的建立[J].中国临床药理学与治疗学, 2015, 20(4): 430-434.
[11]Lim GH, Tan PH, Jara-Lazaro AR, et al.Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival[J].Singapore Med J,2014,55(9):468-472.
[12]Xu Y,Yuan J,Zhang Z,et al.Syndeean-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis[J].Mol Biol Rep, 2012,39(9):8979-8985.
[13]李明武,韩国宏.分子靶向药物治疗晚期胆道肿瘤的研究进展[J]. 临床肝胆病杂志,2014(11):1212-1216.
[14]Phua LC, Ng HW, Yeo AH, et al. Prevalence of K-Ras, B-RAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer[J].Oncol Lett, 2015, 10(4):2519-2526.
[15]Osumi H, Shinozaki E, Osako M, et al. Cetuximab treatment for metastatic colorectal cancer with K-RAS p.G13D mutations improves progression-free survival[J].Mol Clin Oncol, 2015, 3(5):1053-1057.
[16]Yazdi MH, Faramarzi MA, Nikfar S, et al. A comprehensive review of clinical trials on EGFR inhibitors such as cetuximab and panitumumab as monotherapy and in combination for treatment of metastatic colorectal cancer[J].Avicenna J Med Biotechnol, 2015, 7(4):134-144. |